9-113354243-A-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_017688.3(BSPRY):āc.205A>Gā(p.Lys69Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00014 in 1,614,028 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00025 ( 0 hom., cov: 32)
Exomes š: 0.00013 ( 0 hom. )
Consequence
BSPRY
NM_017688.3 missense
NM_017688.3 missense
Scores
1
8
10
Clinical Significance
Conservation
PhyloP100: 2.56
Genes affected
BSPRY (HGNC:18232): (B-box and SPRY domain containing) Predicted to enable ubiquitin protein ligase activity. Predicted to be involved in protein ubiquitination. Predicted to act upstream of or within cellular response to leukemia inhibitory factor. Predicted to be located in cell leading edge; membrane; and perinuclear region of cytoplasm. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.065465).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BSPRY | NM_017688.3 | c.205A>G | p.Lys69Glu | missense_variant | 2/6 | ENST00000374183.5 | |
BSPRY | NM_001317943.2 | c.205A>G | p.Lys69Glu | missense_variant | 2/6 | ||
BSPRY | NM_001317944.2 | c.205A>G | p.Lys69Glu | missense_variant | 2/5 | ||
BSPRY | XM_006717149.4 | c.205A>G | p.Lys69Glu | missense_variant | 2/6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BSPRY | ENST00000374183.5 | c.205A>G | p.Lys69Glu | missense_variant | 2/6 | 1 | NM_017688.3 | P1 | |
BSPRY | ENST00000462085.1 | n.243A>G | non_coding_transcript_exon_variant | 2/5 | 1 |
Frequencies
GnomAD3 genomes AF: 0.000250 AC: 38AN: 152192Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
38
AN:
152192
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000160 AC: 40AN: 249262Hom.: 0 AF XY: 0.000178 AC XY: 24AN XY: 135198
GnomAD3 exomes
AF:
AC:
40
AN:
249262
Hom.:
AF XY:
AC XY:
24
AN XY:
135198
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000129 AC: 188AN: 1461718Hom.: 0 Cov.: 33 AF XY: 0.000135 AC XY: 98AN XY: 727184
GnomAD4 exome
AF:
AC:
188
AN:
1461718
Hom.:
Cov.:
33
AF XY:
AC XY:
98
AN XY:
727184
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000249 AC: 38AN: 152310Hom.: 0 Cov.: 32 AF XY: 0.000242 AC XY: 18AN XY: 74478
GnomAD4 genome
AF:
AC:
38
AN:
152310
Hom.:
Cov.:
32
AF XY:
AC XY:
18
AN XY:
74478
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
17
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 22, 2023 | The c.205A>G (p.K69E) alteration is located in exon 2 (coding exon 2) of the BSPRY gene. This alteration results from a A to G substitution at nucleotide position 205, causing the lysine (K) at amino acid position 69 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T
M_CAP
Benign
T
MetaRNN
Benign
T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M
MutationTaster
Benign
D
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
N
REVEL
Benign
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
P
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at